Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.45 CAD | +1.40% |
|
0.00% | +9.02% |
Jun. 23 | Hamilton Thorne Maintained at Buy at Stifel GMP on No Impact From U.S. IVF Actions; Price Target Kept at C$2.55 | MT |
May. 14 | Hamilton Thorne Q1 Loss Widens Even as Sales Increase | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The company does not generate enough profits, which is an alarming weak point.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 85.78 times its estimated earnings per share for the ongoing year.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+9.02% | 163M | - | ||
+3.77% | 210B | B | ||
+8.83% | 186B | B- | ||
+31.94% | 158B | B- | ||
+33.19% | 113B | A- | ||
+5.25% | 66.13B | A- | ||
+22.41% | 56.25B | B+ | ||
+1.34% | 49B | B+ | ||
-5.92% | 38.16B | A | ||
+1.94% | 35.98B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- HTL Stock
- HTL Stock
- Ratings Hamilton Thorne Ltd.